UBS Group’s Tema Oncology ETF CANC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$635K Buy
+15,119
New +$639K ﹤0.01% 6034
2025
Q4
– Sell
-605
Closed -$17.4K – 10547
2025
Q3
$17.4K Buy
+605
New +$16.1K ﹤0.01% 8250
2025
Q2
– Sell
-223
Closed -$5.37K – 10293
2025
Q1
$5.37K Buy
+223
New +$5.61K ﹤0.01% 9005

Other funds holding CANC

UBS Group's CANC Position: Q3 2026 in Review

UBS Group opened a new position in Tema Oncology ETF (CANC) in Q3 2026: 15,119 shares worth $635K. The stake represents ﹤0.01% of the portfolio and ranks #6034 among its holdings. This is a return to the name: UBS Group previously reported a position in CANC as recently as Q3 2025.

UBS Group first reported a position in CANC in Q1 2025 and has held it in 3 quarters since. 17 funds tracked by Wall St. Rank hold CANC as of Q3 2026.

  • UBS Group held 15,119 shares of Tema Oncology ETF worth $635K as of Q3 2026.
  • Tema Oncology ETF was a new UBS Group position in Q3 2026.
  • Tema Oncology ETF made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #6034 holding.
  • UBS Group first reported a position in Tema Oncology ETF in Q1 2025 and has held it in 3 quarters since.
  • 17 funds tracked by Wall St. Rank held Tema Oncology ETF as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.